Riverpoint Medical announced that it has completed the acquisition of CP Medical. Riverpoint is a portfolio company of Arlington Capital Partners, a Washington, D.C.-area private investment firm specializing in government-regulated industries.
CP Medical is a Norcross, Georgia-based manufacturer of surgical solutions, specializing in products for wound closure as well as for specialty surgical applications. CP Medical also manufactures a comprehensive portfolio of private-label sutures and wound closure products, sold through a global network of distributors, for the veterinary and human medical market.
Headquartered in Portland, Oregon, Riverpoint Medical is a developer, designer and manufacturer of medical devices focused on advanced bio-medical textile technologies. Riverpoint received a majority investment from Arlington Capital Partners in June 2019.
“The addition of CP Medical aligns seamlessly with Riverpoint’s growth strategy and allows the Company to further its commitment to delivering high-quality surgical solutions”, said Gordon Auduong, a Principal at Arlington. “We look forward to leveraging CP Medical’s established relationships to deliver the same level of innovation, excellence, and service that Riverpoint is known with its customers.”
DC Advisory served as financial advisor to Riverpoint Medical and Arlington on the transaction.
According to data captured in the LevinPro HC database, this acquisition marks the 44th Medical Device transaction of 2024. There were 112 Medical Device deals announced during 2023, and 123 announced during 2022.
